This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

VBI Vaccines Beheer

Beheer criteriumcontroles 3/4

De CEO VBI Vaccines is Jeff Baxter, benoemd in May2016, heeft een ambtstermijn van 8.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 893.55K, bestaande uit 78.1% salaris en 21.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.071% van de aandelen van het bedrijf, ter waarde € 400.86. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.9 jaar en 6.6 jaar.

Belangrijke informatie

Jeff Baxter

Algemeen directeur

US$893.5k

Totale compensatie

Percentage CEO-salaris	78.1%
Dienstverband CEO	8.3yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	6.9yrs
Gemiddelde ambtstermijn bestuur	6.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jeff Baxter's beloning veranderd ten opzichte van VBI Vaccines's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$894k	US$698k	-US$94m
Sep 30 2023	n/a	n/a	-US$115m
Jun 30 2023	n/a	n/a	-US$119m
Mar 31 2023	n/a	n/a	-US$120m
Dec 31 2022	US$2m	US$678k	-US$113m
Sep 30 2022	n/a	n/a	-US$111m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$3m	US$605k	-US$70m
Sep 30 2021	n/a	n/a	-US$66m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$2m	US$535k	-US$46m
Sep 30 2020	n/a	n/a	-US$42m
Jun 30 2020	n/a	n/a	-US$45m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$1m	US$500k	-US$55m
Sep 30 2019	n/a	n/a	-US$63m
Jun 30 2019	n/a	n/a	-US$62m
Mar 31 2019	n/a	n/a	-US$66m
Dec 31 2018	US$1m	US$465k	-US$64m
Sep 30 2018	n/a	n/a	-US$56m
Jun 30 2018	n/a	n/a	-US$50m
Mar 31 2018	n/a	n/a	-US$43m
Dec 31 2017	US$826k	US$450k	-US$39m

Compensatie versus markt: De totale vergoeding ($USD 893.55K ) Jeff } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 483.75K ).

Compensatie versus inkomsten: De vergoeding van Jeff is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jeff Baxter (63 yo)

8.3yrs

Tenure

US$893,547

Compensatie

Mr. Jeffery R. Baxter, also known as Jeff, FCMA, has been the Chief Executive Officer and President of VBI Vaccines Inc. since May 2016. Mr. Baxter has been the Chief Executive Officer and President of VBI...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffery Baxter	President	8.3yrs	US$893.55k	0.071% € 400.9
Nell Beattie	CFO, Head of Corporate Development & Director	1.3yrs	geen gegevens	0.0079% € 44.9
David Anderson	Chief Scientific Officer	8.3yrs	US$564.56k	0.017% € 97.7
Francisco Diaz-Mitoma	Chief Medical Officer	8.5yrs	US$549.22k	0.049% € 277.0
Nicole Anderson	Director of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Athena Kartsaklis	Senior VP of Finance	6.9yrs	geen gegevens	geen gegevens
Avi Mazaltov	Global Head of Manufacturing & GM of SciVac	7.3yrs	geen gegevens	0.025% € 139.7
Misha Nossov	Senior VP of Global Commercial Supply Strategy & Head of Europe	4.6yrs	geen gegevens	geen gegevens
T. Buckley	Senior Vice President of Business Development	4.6yrs	geen gegevens	geen gegevens
John Dillman	Chief Commercial Officer	2.1yrs	geen gegevens	geen gegevens

6.9yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LO9A is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffery Baxter	President	8.3yrs	US$893.55k	0.071% € 400.9
Nell Beattie	CFO, Head of Corporate Development & Director	1.3yrs	geen gegevens	0.0079% € 44.9
Steven S. Gillis	Independent Chairperson of the Board	8.3yrs	US$194.03k	0.0098% € 55.6
Denis Burger	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Peter Patriarca	Member of Scientific Advisory Board	6.6yrs	geen gegevens	geen gegevens
Stanley Plotkin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Damian Braga	Chairperson of the Commercial Advisory Board & Independent Director	4.4yrs	US$105.18k	0% € 0
Michel De Wilde	Independent Director and Chair of Scientific & Clinical Advisory Board	8.3yrs	US$107.68k	0.0058% € 33.0
Blaine McKee	Independent Director	5.6yrs	US$120.18k	0% € 0
Joanne Cordeiro	Independent Director	5.3yrs	US$127.68k	0% € 0
Robert Pass	Member of Scientific Advisory Board	6.6yrs	geen gegevens	geen gegevens
Adam Finn	Member of Scientific Advisory Board	6.6yrs	geen gegevens	geen gegevens

6.6yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LO9A wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.6 jaar).

This company listing is no longer active

VBI Vaccines Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

VBI Vaccines Inc., Annual General Meeting, Jun 25, 2024

Insufficient new directors

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

Recent updates

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc., Annual General Meeting, Jun 25, 2024

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Second quarter 2023 earnings released: US$5.18 loss per share (vs US$5.31 loss in 2Q 2022)

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

Now 20% undervalued after recent price drop

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 24% undervalued after recent price drop

First quarter 2023 earnings released: US$3.22 loss per share (vs US$2.47 loss in 1Q 2022)

Insufficient new directors

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Third quarter 2022 earnings released: US$0.098 loss per share (vs US$0.062 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.098 loss per share (vs US$0.062 loss in 3Q 2021)

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.068 loss in 2Q 2021)

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

First quarter 2022 earnings released: US$0.082 loss per share (vs US$0.07 loss in 1Q 2021)

Forecast to breakeven in 2024

VBI Vaccines Inc. Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

VBI Vaccines Inc. Announces PreHevbrio Availability in the United States for the Prevention of Hepatitis B in Adults

Forecast to breakeven in 2024

No longer forecast to breakeven

VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union

VBI Vaccines Inc. Announces Prehevbrio [Hepatitis B Vaccine (Recombinant)] Recommends by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults

VBI Vaccines Inc. Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients

Forecast to breakeven in 2024

VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada

VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021

VBI Vaccines Announces U.S. Food and Drug Administration Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd